All News

Study will analyze whether cognitive behavioral therapy telehealth can lower headache days and disability as effectively as cognitive behavioral therapy plus a preventive medication for migraine.

Moxifloxacin hydrochloride (Avelox) is indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria.

Mucinex DM is an expectorant and cough suppressant.

Meta-analysis of randomized controlled trials adds to growing evidence around certain antihypertensive drug classes showing promise for primary or secondary prevention of diabetes.

Part 3 in a series outlining 5 crucial steps pharmacies can take to enhance patient engagement and lower operational costs.

Although the guidance has created some confusion around pharmacists’ responsibilities on the federal and state levels, Lanton said it will take time to find cohesive solutions.

Health care professionals need to work closely with patients in understanding polypharmacy and the risk/benefit of pharmacotherapy.

Analysis supports positive lifestyle habits, such as exercising and quitting smoking, investigators say.

Investigators from NYU’s Grossman School of Medicine sound alarm on treatment gap and suggest ways to remove barriers, as opioid overdoses soar to historic levels.

Pharmacists can play an important role in helping ensure compliance with prescribed medications, which can help seniors maintain their health and quality of life while aging at home.

Survey finds that 91% of health care providers and 67% of people with migraines feel that individuals who are able to successfully manage stress and mental health conditions can also better manage the symptoms of migraine.

Cangrelor (Kengreal) is indicated as an adjunct to percutaneous coronary intervention for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis.

Aftera is an emergency contraceptive that reduces the chance of pregnancy after unprotected sex.

Globally, more than 40 million patients are currently taking an ACE inhibitor, primarily for the treatment of high blood pressure and heart failure.

Immunoinformatics allows researchers to develop vaccines without microbial culturing, thus saving time and money.

Tardive dyskinesia is often caused by the use of dopamine receptor blocking agents, most commonly antipsychotics, for at least a few months.

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.

A systemic review found that recombinant zoster vaccination is more cost effective than no vaccine or the previously available zoster vaccine live.

Study suggests that health care providers should discuss with patients whether they are using any integrative medicine strategies, which ones, and why.

Researchers recommend having a low clinical threshold for the diagnosis of Hashimoto’s encephalopathy in patients who reveal no apparent cause for their altered mental status, given the heterogenous nature of the condition’s presentation.

Last year, the majority of new drug approvals were for small molecules, including treatments for HIV, cancer, infections, heart and kidney disease, and neurological disorders.

On this week's episode, Joanna continues her conversation with Allyson Brennan, Founder of Emogene & Co, PharmD, about skincare, the importance of a healthy skin barrier, Vitamin C, and work-life balance.

Kayexalate is a potassium binder indicated for the treatment of hyperkalemia.

Senokot-S is indicated for constipation relief.

The approval is based on results of the phase 3 study, ARASENS, that demonstrated a statistically significant increase in overall survival, the trial’s primary endpoint.

Preliminary data from the ongoing dose-escalation portion of the clinical trial, show dose-dependent anti-tumor activity when combined with standard-dose Libtayo.

Use of hormone therapy to treat prostate cancer may require more consideration by health care providers as new study shows the therapy may increase the risk of heart disease.

Based on overall response rate, acalabrutinib in tablet form is now FDA approved for all approved indications, enabling co-administration alongside a proton pump inhibitor.